The European Commission's health technology assessment proposal is broad in its intention and may offer future opportunities toward EU-wide consideration of the value of personalized medicine, promoting the cooperation between national agencies and avoiding a duplication of work and inefficient use of resources by national bodies.
That is the view of Hogan Lovells' Riccardo Fruscalzo, expressed in a recent interview with Medtech Insight. However, says his colleague Elisabethann Wright, it is too early to say if...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?